Literature DB >> 832246

Survival with inoperable lung cancer: an integration of prognostic variables based on simple clinical criteria.

V J Lanzotti, D R Thomas, L E Boyle, T L Smith, E A Gehan, M L Samuels.   

Abstract

The objectives are to identify and integrate through regression analysis those fundamental clinical variables predicting survival of patients with inoperable lung cancer managed in a modern setting. Median survival time from first treatment in 129 patients with limited disease and 187 patients with extensive disease was 36 and 14 weeks, respectively. Within the proposed survival model for limited disease, weight loss was the major prognosticator followed by symptom status, supraclavicular metastases, and age. Within extensive disease, symptom status and age were dominant variables followed by weight loss and metastases to liver, opposite hemithorax, brain, and bone. Survival by cell type was similar within the limited and extensive disease groups. The data identify the essential factors which must be controlled or accounted for in studies analyzing survival as a dependent variable.

Entities:  

Mesh:

Year:  1977        PMID: 832246     DOI: 10.1002/1097-0142(197701)39:1<303::aid-cncr2820390147>3.0.co;2-u

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  16 in total

Review 1.  Metabolic alteration in patients with cancer: nutritional implications.

Authors:  Y Sakurai; S Klein
Journal:  Surg Today       Date:  1998       Impact factor: 2.549

Review 2.  [Short-term induction and cyclic maintenance therapy in inoperable small cell bronchial cancer].

Authors:  N Niederle; W Krischke; U Schulz; C G Schmidt; S Seeber
Journal:  Klin Wochenschr       Date:  1982-08-16

3.  Chemotherapy of non-small cell lung cancer: clinical trials at the Memorial Sloan-Kettering Cancer Center.

Authors:  R J Gralla; R E Wittes; E S Casper; D P Kelsen; E Cvitkovic; G B Magill; S E Krown; R B Golbey
Journal:  World J Surg       Date:  1981-09       Impact factor: 3.352

4.  Determinants of survival in advanced non--small-cell lung cancer in the era of targeted therapies.

Authors:  Joshua Bauml; Rosemarie Mick; Yu Zhang; Christopher D Watt; Anil Vachani; Charu Aggarwal; Tracey Evans; Corey Langer
Journal:  Clin Lung Cancer       Date:  2013-07-01       Impact factor: 4.785

5.  Pretreatment clinical prognostic factors in patients with stage IV non-small cell lung cancer (NSCLC) treated with chemotherapy.

Authors:  Branislav Jeremic; Biljana Milicic; Aleksandar Dagovic; Jasna Aleksandrovic; Nebojsa Nikolic
Journal:  J Cancer Res Clin Oncol       Date:  2003-03-07       Impact factor: 4.553

6.  A randomized trial fo three cisplatin-containing regimens in advanced non-small-cell lung cancer (NSCLC): a study of the Umbrian Lung Cancer Group.

Authors:  L Crino; M Tonato; S Darwish; M L Meacci; E Corgna; F Di Costanzo; F Buzzi; G Fornari; E Santi; E Ballatori
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 7.  A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors.

Authors:  D J Stewart
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 8.  Extended resection for higher-stage non-small-cell lung cancer.

Authors:  J D Luketich; D E van Raemdonck; R J Ginsberg
Journal:  World J Surg       Date:  1993 Nov-Dec       Impact factor: 3.352

Review 9.  Quality of life during clinical trials: conceptual model for the Lung Cancer Symptom Scale (LCSS).

Authors:  P J Hollen; R J Gralla; M G Kris; C Cox
Journal:  Support Care Cancer       Date:  1994-07       Impact factor: 3.603

10.  Prognostic factors for survival in terminal lung cancer patients.

Authors:  R S Schonwetter; B E Robinson; G Ramirez
Journal:  J Gen Intern Med       Date:  1994-07       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.